Furthermore, key baseline data, including the classification of patients as Type I or Type II diabetes, the specific baseline treatment regimens (non-insulin medications, insulin, or no treatment), the duration of diabetes prior to the intervention, and existing diabetic complications (such as vasculopathy, neuropathy, or retinopathy), were not available for individual patients. This evidence concerns the gene INS and vascular disorder.